Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 4SC-101; SC-12267

Latest Information Update: 21 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4SC
  • Developer 4SC; University of Munich
  • Class Amides; Anti-inflammatories; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Disease-modifying antirheumatics; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Interferon gamma inhibitors; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Inflammatory bowel diseases; Rheumatoid arthritis

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 20 Oct 2016 Discontinued - Phase-II for Inflammatory bowel disease in Germany, Bulgaria, Romania (PO) (4SC pipeline; October 2016)
  • 20 Oct 2016 Discontinued - Phase-II for Rheumatoid arthritis (Combination therapy, Monotherapy) in Bulgaria, Czech Republic, Romania, Poland (PO) (4SC pipeline; October 2016)
  • 20 Oct 2016 Discontinued - Phase-II for Rheumatoid arthritis in Germany (PO) (4SC pipeline; October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top